Mr
Michael
Nelson

partner & european and uk patent attorney

Basel Office

Chemistry

Telephone. +41(0) 61 225 4480
Mobile. +41(0) 78 698 8690
Email. [email protected]

Experience

Michael is a specialist patent attorney in the in the pharmaceutical field and has more than 20 years of experience at all stages of a product, from early phase discovery to defending marketed pharmaceutical products. Michael acts for a wide range of clients including multinationals, SMEs, universities and research organisations.

Prior to joining HGF Michael worked "in-house" as a patent attorney for 13 years for AstraZeneca and use this experience and insight to advise clients and develop IP strategies that are focused on their commercial objectives.

His work covers patent drafting, global prosecution, patent term extensions and SPCs, freedom to operate analysis and opinions, regulatory exclusivity as well as significant experience in IP due diligence evaluation. Michael also handles EPO oppositions and appeals for his clients.

Qualifications

Patent Attorney

Chartered (UK)
European


BSC

Physics (First Class Honours)

Publications

Opposition case studies

View publication online

Swiss Institute for Translational and Entrepreneurial Medicine

View publication online

Conferences: 2022

June 27th 2022

Webinar: A comparison of IP Practice in EU, US and JP for new medical use and method of treatment patenting

Speaker

Event details

Conferences: 2021

May 10th 2021

Intellectual Property - Are you protecting your business ideas?

Speaker

Event details

Conferences: 2020

March 3rd 2020

IP in Healthcare Conference 2020

Speaker

Event details

Conferences: 2019

June 27th 2019

Update on the CRISPR IP Saga and lessons to be learnt - Basel

Speaker

Event details

March 14th 2019

IP in Healthcare Conference 2019 - London & Manchester

Speaker

Event details

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.